Purpose: Mutations in SZT2 have been previously reported in several cases of early onset epilepsy and intellectual disability. In this study we investigate potential causal mutations in two male siblings affected by early onset epilepsy, intellectual disability and macrocephaly.
and intellectual disability. In this study we investigate potential causal mutations in two male siblings affected by early onset epilepsy, intellectual disability and macrocephaly.
Methods: We use family-based whole-exome sequencing to identify candidate variants.
Results:
We report the identification of two potential causal SZT2 mutations in compound heterozygous state. We observe considerable differences in the clinical phenotype severity of the two affected individuals. The cerebral MRI revealed no abnormalities in the older affected brother, while in the youngest one it revealed a right frontal polymicrogiria. Moreover, while good seizure control was achieved in the older affected individual the younger brother is affected by pharmacoresistant epilepsy, progressive spastic paraplegia, cortical myoclonus and a more severe intellectual disability.
We also analyzed the relative location of the reported pathogenic mutations in the SZT2 protein.
Conclusion:
Variable phenotypic expressivity is observed for this condition, while the location and type of mutations in SZT2 also has a potential impact on epilepsy severity. These findings extend our knowledge of epileptogenic conditions related to SZT2 and mTOR signaling.
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In 2009 the SZT2 gene was shown to influence seizure threshold and epileptogenesis in mice [4] , and the protein has been implicated in resistance to oxidative stress [5] . Recently, a role of SZT2 protein in mTOR signaling has been demonstrated in human [6] . So far six independent reports have identified 16 different biallelic SZT2 mutations (in compound heterozygous or homozygous state) in eleven individuals with epilepsy and/or intellectual disability (ID) [7] [8] [9] [10] [11] [12] (Table 1) . These reports describe epilepsy of varying severity and ID in eight unrelated children, as well as three brothers with moderate ID without epilepsy. Moreover, in these reports seven patients also present macrocephaly, which appears to be the most significant physical sign of the phenotype.
Here, we report two mutations in SZT2 in compound heterozygous state in two young adult siblings with early onset seizures, ID and macrocephaly. We compare the different SZT2 mutations and clinical phenotypes previously reported and investigate their relative location in the protein and their relation to phenotype severity.
Patients, Materials and Methods

Patients
Three brothers were born to healthy, Caucasian, nonconsanguineous parents in the study family ( 
Sequencing and analysis
DNA was extracted from peripheral blood. Whole exome sequencing (WES) and Sanger sequencing of the candidate variants were performed as described in the supplement.
Candidate variants were selected from the whole exome based on a combination of predefined criteria (see supplement). Notably, the variant must segregate in the family in a recessive mode of inheritance either in homozygous or in compound heterozygous state, or alternatively as X-linked recessive. A potential scenario of parental mosaicism was also investigated.
Results
Clinical phenotype
Individual II.1 was born at term after an uneventful pregnancy. An absolute and relative macrocephaly (head circumference: +4.3 SD; normal values in both parents) was noted at birth.
Developmental delay was observed early in life and at 8 months of age he developed focal motor to bilateral tonic-clonic seizures. Sodium valproate and vigabatrin were started with good control of the seizures, and then seizures weaned off, leading to a long-lasting seizure-free period until the age of 16 years. Since then he experienced few focal seizures, controlled at 22 years with valproate and lacosamide. Although a good seizure control was achieved, the patient developed a moderate ID and autism spectrum disorder features such as deficits in social interaction and communication. Now he is 29 years old, is able to walk unassisted and has sufficient autonomy in daily life, the macrocephaly persists. His neurological examination is normal, without evidence of spasticity or cranial nerve or cerebellar dysfunction. Brain magnetic resonance imaging (MRI) at the ages of 3, 6 and 17 years were normal. Genetic testing included standard karyotype analysis, FMR1 gene testing for fragile X syndrome, and mutation screening of TSC1, TSC2 and PTEN genes, all of which gave normal results.
Individual II.4 was born at term after an uneventful pregnancy. At birth he was diagnosed with absolute and relative macrocephaly (head circumference: +4.4 SD) and agenesis of the left kidney.
Focal seizures began 4 days after birth and were controlled with phenytoin and later with carbamazepine, which was weaned off at 8 months. Early interictal EEG showed multifocal frontotemporal spikes, but was normal at the age of 14 months. Focal to bilateral tonic seizure reappeared at 
Genetic and computational analysis
After filtering the variants as described in the supplementary material, only one candidate scenario The relative locations of Mut1 and Mut2 in the SZT2 protein are provided in Fig. 1B . Their predicted effect on protein stability is described in the supplement. Table 1 provides a summary of the reported clinical features of all known patients with SZT2 mutations.
Discussion
We have identified and characterized two compound heterozygous variants in SZT2 in two patients with epilepsy, intellectual disability, and macrocephaly. Both variants are rare and one has not been previously reported. They are predicted to be deleterious and destabilizing, and one might affect splicing. This study is also the first to report candidate SZT2 pathogenic mutations in two related individuals affected with early-onset epilepsy and provides the longest follow up period.
Comparison of the relative location of the reported pathogenic mutations in SZT2 indicates that cases with severe drug-resistant epilepsy tend to have truncating (nonsense) mutations at the protein Nterminus (Fig. 1B) . The more severe phenotypes could result from a severely truncated protein, or from NMD and haploinsufficiency. The molecular function and activity of the SZT2 protein is largely unknown and a proper molecular characterization is needed, involving structure determination and identification of functional sites.
The two affected individuals show considerable differences in clinical phenotype severity: the cerebral MRI revealed no abnormalities in II.1, while in II.4 it revealed a right frontal polymicrogiria;
moreover II.4 presents a drug-resistant epileptic encephalopathy associated with severe cognitive ID and progressive spastic paraplegia, while a milder form of epilepsy and cognitive impairment without clear neurological deficits is observed in the brother II.1. The clinical variability in SZT2-related conditions has already been described in the eleven previously reported patients, whose clinical features are summarized in Table 1 and in the Supplement 2 table. Hypotonia was the more frequent neurological sign, reported in seven patients; in two cases there was an adjunctive abnormal motor pattern with chorea [11] or Choreoathetosis [9] ; contractures were reported in two other children [7, 11] . There are no reports of tethered-cord in the published cases. Although this small patient group does not reveal a constant and characteristic phenotype, we observe that the association of epilepsy, psychomotor retardation/intellectual disability and macrocephaly is a recurrent clinical pattern in the presence of SZT2 mutations.
To investigate the determinants of this variable expressivity one could examine the potential impact of 
